BACKGROUND: We sought to profile Atypical Meningioma in a high-throughput manner to better understand the altered signaling within these tumors and specifically the kinases altered in recurrent atypical meningioma. Kinomic Profiles could be used to identify prognostic biomarkers for responders/non-responders to classify future patients that are unlikely to benefit from current therapies. Directly these results could be used to identify drug-actionable kinase targets as well. METHODS: Peptide-substrate microarray kinase activity analysis was conducted with a PamStation®12 analyzing the tyrosine kinome in each tumor kinetically against ~144 target peptides. These data were then analyzed relative to clinical outcome (e.g., tumor recurrence). RESULTS: 3 major clusters of atypical meningiomas were identified with highly variant peptides primarily being targets of EGFR family, ABL, BRK and BMX kinases. Kinomic analysis of recurrent atypical meningiomas indicated patterns of increased phosphorylation of BMX, TYRO3 and FAK substrates as compared to non-recurrent tumors. CONCLUSION: The atypical meningiomas profiled here exhibited molecular sub-clustering that may have phenotypic corollaries predictive of outcome. Recurrent tumors had increases in kinase activity that may predict resistance to current therapies, and may guide selection of directed therapies. Taken together these data further the understanding of kinomic alteration in atypical meningioma, and the processes that may not only mediate recurrence, but additionally may identify kinase targets for intervention.
BACKGROUND: We sought to profile Atypical Meningioma in a high-throughput manner to better understand the altered signaling within these tumors and specifically the kinases altered in recurrent atypical meningioma. Kinomic Profiles could be used to identify prognostic biomarkers for responders/non-responders to classify future patients that are unlikely to benefit from current therapies. Directly these results could be used to identify drug-actionable kinase targets as well. METHODS: Peptide-substrate microarray kinase activity analysis was conducted with a PamStation®12 analyzing the tyrosine kinome in each tumor kinetically against ~144 target peptides. These data were then analyzed relative to clinical outcome (e.g., tumor recurrence). RESULTS: 3 major clusters of atypical meningiomas were identified with highly variant peptides primarily being targets of EGFR family, ABL, BRK and BMX kinases. Kinomic analysis of recurrent atypical meningiomas indicated patterns of increased phosphorylation of BMX, TYRO3 and FAK substrates as compared to non-recurrent tumors. CONCLUSION: The atypical meningiomas profiled here exhibited molecular sub-clustering that may have phenotypic corollaries predictive of outcome. Recurrent tumors had increases in kinase activity that may predict resistance to current therapies, and may guide selection of directed therapies. Taken together these data further the understanding of kinomic alteration in atypical meningioma, and the processes that may not only mediate recurrence, but additionally may identify kinase targets for intervention.
Authors: Arend H Sikkema; Sander H Diks; Wilfred F A den Dunnen; Arja ter Elst; Frank J G Scherpen; Eelco W Hoving; Rob Ruijtenbeek; Piet J Boender; Rik de Wijn; Willem A Kamps; Maikel P Peppelenbosch; Eveline S J M de Bont Journal: Cancer Res Date: 2009-06-30 Impact factor: 12.701
Authors: Christian Mawrin; Tina Sasse; Elmar Kirches; Siegfried Kropf; Thomas Schneider; Christoph Grimm; Claudia Pambor; Christian K Vorwerk; Raimund Firsching; Uwe Lendeckel; Knut Dietzmann Journal: Clin Cancer Res Date: 2005-06-01 Impact factor: 12.531
Authors: J Boström; B Meyer-Puttlitz; M Wolter; B Blaschke; R G Weber; P Lichter; K Ichimura; V P Collins; G Reifenberger Journal: Am J Pathol Date: 2001-08 Impact factor: 4.307
Authors: Winward Choy; Won Kim; Daniel Nagasawa; Stephanie Stramotas; Andrew Yew; Quinton Gopen; Andrew T Parsa; Isaac Yang Journal: Neurosurg Focus Date: 2011-05 Impact factor: 4.047
Authors: Manish K Aghi; Bob S Carter; Garth R Cosgrove; Robert G Ojemann; Sepideh Amin-Hanjani; Robert L Martuza; William T Curry; Fred G Barker Journal: Neurosurgery Date: 2009-01 Impact factor: 4.654
Authors: Ricardo J Komotar; J Bryan Iorgulescu; Daniel M S Raper; Eric C Holland; Kathryn Beal; Mark H Bilsky; Cameron W Brennan; Viviane Tabar; Jonathan H Sherman; Yoshiya Yamada; Philip H Gutin Journal: J Neurosurg Date: 2012-08-24 Impact factor: 5.115
Authors: Ashley N Gilbert; Rachael S Shevin; Joshua C Anderson; Catherine P Langford; Nicholas Eustace; G Yancey Gillespie; Raj Singh; Christopher D Willey Journal: J Vis Exp Date: 2016-06-09 Impact factor: 1.355
Authors: Colleen M Britain; Andrew T Holdbrooks; Joshua C Anderson; Christopher D Willey; Susan L Bellis Journal: J Ovarian Res Date: 2018-02-05 Impact factor: 4.234
Authors: Koshi Yamada; Zhi-Qiang Huang; Milan Raska; Colin Reily; Joshua C Anderson; Hitoshi Suzuki; Hiroyuki Ueda; Zina Moldoveanu; Krzysztof Kiryluk; Yusuke Suzuki; Robert J Wyatt; Yasuhiko Tomino; Ali G Gharavi; Amy Weinmann; Bruce A Julian; Christopher D Willey; Jan Novak Journal: Kidney Int Rep Date: 2017-07-19